NASDAQ:RYTM Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis $98.83 +1.12 (+1.15%) As of 09/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rhythm Pharmaceuticals alerts:Sign Up Key Stats Today's Range$97.54▼$100.7650-Day Range$96.77▼$117.6052-Week Range$74.50▼$122.20Volume598,517 shsAverage Volume526,181 shsMarket Capitalization$6.77 billionP/E RatioN/ADividend YieldN/APrice Target$140.67Consensus RatingModerate Buy Company Overview Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases of obesity and related metabolic disorders. The company’s research is centered on the melanocortin-4 receptor (MC4R) pathway, which plays an important role in regulating hunger and energy balance. Rhythm’s primary product is IMCIVREE (setmelanotide), an MC4R agonist. In the United States, IMCIVREE is approved for chronic weight management in adults and children at least 2 years old with obesity and certain genetically confirmed conditions affecting the MC4R pathway, including pro-opiomelanocortin, proprotein convertase subtilisin/kexin type 1 and leptin receptor deficiencies, as well as Bardet-Biedl syndrome. The company is also advancing research intended to expand treatment options for additional rare metabolic diseases. Rhythm was founded in 2008 and is headquartered in Boston, Massachusetts. Its commercial and development activities primarily serve patients in the United States and other international markets where IMCIVREE has received regulatory authorization. David R. Meeker has served as the company’s chief executive officer and chairman.AI Generated. May Contain Errors. Read More Rhythm Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreRYTM MarketRank™: Rhythm Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat, and ranked 392nd out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on no strong buy ratings, 17 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialRhythm Pharmaceuticals has a consensus price target of $140.67, representing about 42.3% upside from its current price of $98.83.Amount of Analyst CoverageRhythm Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rhythm Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($2.86) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -31.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -31.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 47.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rhythm Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.98% of the float of Rhythm Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 21.89, which indicates bearish sentiment.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently increased by 1.46%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.40 News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Rhythm Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest2 people have searched for RYTM on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,508,337.00 in company stock.Percentage Held by Insiders5.90% of the stock of Rhythm Pharmaceuticals is held by insiders.Percentage Held by InstitutionsRhythm Pharmaceuticals has minimal institutional ownership at this time.Read more about Rhythm Pharmaceuticals' insider trading history. Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RYTM Stock News HeadlinesRhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated at Wolfe ResearchSeptember 19 at 1:54 AM | americanbankingnews.comRBC Capital Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM)September 17, 2026 | theglobeandmail.com“Elon Is Not Showing This Publicly, But I Saw It”Elon Musk quietly filed a patent for a new AI invention while attention focused on the SpaceX IPO. Jeff Brown, founder of Brownstone Research, calls it M.A.G.I. Venture capitalist Jason Calacanis, who turned $100,000 into $100 million from Uber's IPO, previewed the technology privately and called it the best selling product he has ever seen. | Brownstone Research (Ad)J.P. Morgan Remains a Buy on Rhythm Pharmaceuticals (RYTM)September 17, 2026 | theglobeandmail.comWolfe Research Initiates Rhythm Pharmaceuticals at OutperformSeptember 17, 2026 | marketscreener.comMRhythm Pharmaceuticals (NASDAQ:RYTM) Shares Down 5.3% After Insider SellingSeptember 17, 2026 | americanbankingnews.comRhythm Pharmaceuticals (NASDAQ:RYTM) CEO Sells $5,133,500.00 in StockSeptember 15, 2026 | insidertrades.comRhythm Pharmaceuticals (NASDAQ:RYTM) CFO Sells $6,620,146.04 in StockSeptember 2, 2026 | insidertrades.comSee More Headlines RYTM Stock Analysis - Frequently Asked Questions How have RYTM shares performed this year? Rhythm Pharmaceuticals' stock was trading at $107.04 at the start of the year. Since then, RYTM shares have decreased by 7.7% and is now trading at $98.83. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.73) EPS for the quarter, beating analysts' consensus estimates of ($0.81) by $0.08. The business's quarterly revenue was up 46.9% on a year-over-year basis. Read the conference call transcript. When did Rhythm Pharmaceuticals IPO? Rhythm Pharmaceuticals (RYTM) raised $106 million in an IPO on Thursday, October 5th 2017. The company issued 7,050,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager. Who are Rhythm Pharmaceuticals' major shareholders? Top institutional investors of Rhythm Pharmaceuticals include BlackRock Inc. (8.98%), Primecap Management Co. CA (4.62%), Jupiter Topco LLC (1.35%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.75%). Insiders that own company stock include David P Meeker, Hunter C Smith, Yann Mazabraud, Jennifer Kayden Lee, Pamela J Cramer, Joseph Shulman, Lynn A Tetrault, Jennifer L Good, Alastair Garfield and Christopher Paul German. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/04/2026Today9/21/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 RYTM's financial health is in the Green zone, according to TradeSmith. RYTM has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RYTM CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees414Year Founded2008Price Target and Rating Average Price Target for Rhythm Pharmaceuticals$140.67 High Price Target$160.00 Low Price Target$100.00 Potential Upside/Downside+42.3%Consensus RatingModerate Buy Rating Score (0-4)2.76 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($3.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$196.54 million Net Margins-85.59% Pretax Margin-85.14% Return on Equity-159.87% Return on Assets-44.00% Debt Debt-to-Equity RatioN/A Current Ratio3.45 Quick Ratio3.20 Sales & Book Value Annual Sales$189.76 million Price / Sales35.69 Cash FlowN/A Price / Cash FlowN/A Book Value$2.08 per share Price / Book47.51Miscellaneous Outstanding Shares68,530,000Free Float64,490,000Market Cap$6.77 billion OptionableOptionable Beta1.97 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:RYTM) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our PartnersThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored10% yields… from a gold security?Most stocks yield under 2%. Even gold stocks average less than 1%. One gold security, backed by one of the wor...Golden Portfolio | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
